We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

4 hedge funds and large institutions have $41.4M invested in Plus Therapeutics in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

3% more capital invested

Capital invested by funds: $40.2M → $41.4M (+$1.2M)

88% less call options, than puts

Call options by funds: $52K | Put options by funds: $449K

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
$52K
Puts
$449K
Net Calls
-$397K
Net Calls Change
-$33K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$6.73M

Top Sellers

Rank Fund Capital Flow
1
Allianz Asset Management
Allianz Asset Management
Germany
-$517K
2
DCM
Driehaus Capital Management
Illinois
-$117K
3
EEG
E.E. Geduld
-$68K
4
PPA
Parametric Portfolio Associates
Washington
-$29K
5
PA
Profund Advisors
Maryland
-$28K
Name Holding Trade Value Shares
Change 		Change in
Stake
DADC
76
D.A. Davidson & Co
Montana
– -$2K – –
DCM
77
Driehaus Capital Management
Illinois
– -$117K – –
EEG
78
E.E. Geduld
– -$68K – –
PPA
79
Parametric Portfolio Associates
Washington
– -$29K – –
PA
80
Profund Advisors
Maryland
– -$28K – –
1 2 3
4

PSTV Hedge Fund Activity: Q2 2014 in Review

4 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q2 2014, worth a combined $41.4M — up 3% from $40.2M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PSTV positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $6.73M. The largest seller was Allianz Asset Management, cutting an estimated $517K.

  • 4 institutional investors held Plus Therapeutics (PSTV) as of Q2 2014, up from 3 in Q1 2014.
  • Funds reported $41.4M of Plus Therapeutics stock for Q2 2014, up 3% quarter-over-quarter.
  • 1 fund opened new Plus Therapeutics positions in Q2 2014 and 0 closed out, a net change of +1 holder.
  • The largest Plus Therapeutics buyer in Q2 2014 was Sabby Management, an estimated $6.73M added.
  • The largest Plus Therapeutics seller in Q2 2014 was Allianz Asset Management, an estimated $517K sold.

Based on aggregated 13F filings for Q2 2014.